Tonix Pharmaceuticals Holding Corp. (TNXP) shared news on Monday that the U.S. Food and Drug Administration (FDA) has certified their drug, TNX-2900 under the rare pediatric disease category. The classification specifies its application for treating Prader-Willi syndrome (PWS) in children and adolescents.
TNX-2900 is an exclusive formulation of oxytocin that is potentiated by magnesium and administered intranasally.
Prader-Willi syndrome is notable for being the leading genetic contributor to life-threatening obesity in children. Currently, it has no approved treatments on the market.
